1. Structural and functional analysis of the Klebsiella pneumoniae MazEF toxin–antitoxin system
- Author
-
Do-Hee Kim, Chenglong Jin, Bong-Jin Lee, and Sung-Min Kang
- Subjects
mazef ,Klebsiella pneumoniae ,medicine.disease_cause ,Biochemistry ,03 medical and health sciences ,medicine ,General Materials Science ,Ribonuclease ,030304 developmental biology ,Genetics ,0303 health sciences ,Mutation ,Crystallography ,biology ,Chemistry ,Toxin ,030302 biochemistry & molecular biology ,ribonuclease activity ,toxin–antitoxin systems ,General Chemistry ,structural homologs ,Condensed Matter Physics ,biology.organism_classification ,Toxin-antitoxin system ,klebsiella pneumoniae ,Dodecameric protein ,QD901-999 ,biology.protein ,Antitoxin ,Bacteria - Abstract
Bacterial toxin–antitoxin (TA) systems correlate strongly with physiological processes in bacteria, such as growth arrest, survival and apoptosis. Here, the first crystal structure of a type II TA complex structure of Klebsiella pneumoniae at 2.3 Å resolution is presented. The K. pneumoniae MazEF complex consists of two MazEs and four MazFs in a heterohexameric assembly. It was estimated that MazEF forms a dodecamer with two heterohexameric MazEF complexes in solution, and a truncated complex exists in heterohexameric form. The MazE antitoxin interacts with the MazF toxin via two binding modes, namely, hydrophobic and hydrophilic interactions. Compared with structural homologs, K. pneumoniae MazF shows distinct features in loops β1–β2, β3–β4 and β4–β5. It can be inferred that these three loops have the potential to represent the unique characteristics of MazF, especially various substrate recognition sites. In addition, K. pneumoniae MazF shows ribonuclease activity and the catalytic core of MazF lies in an RNA-binding pocket. Mutation experiments and cell-growth assays confirm Arg28 and Thr51 as critical residues for MazF ribonuclease activity. The findings shown here may contribute to the understanding of the bacterial MazEF TA system and the exploration of antimicrobial candidates to treat drug-resistant K. pneumoniae.
- Published
- 2021